๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

A phase II study of mitoxantrone in advanced squamous cell cancer of the head and neck

โœ Scribed by H. Wheeler; R. L. Woods; J. Page; J. Levi

Publisher
Springer US
Year
1990
Tongue
English
Weight
186 KB
Volume
8
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

โœฆ Synopsis

Twenty patients with advanced squamous cell carcinomas (SCC) of the head and neck were entered into a phase II study of mitoxantrone at a dosage of either 12 mg/m2 or 14 mg/m2 given at 3 weekly intervals. None of the patients had received prior chemotherapy. One patient had a partial remission. Two patients died from unrelated causes. One patient withdrew from the trial prior to receiving any chemotherapy. Sixteen patients either failed to respond or progressed during the course of the treatment. Side effects included nausea and vomiting in 6 patients and neutropenia in 6 patients. This study failed to detect a significant response of squamous cell carcinomas of the head and neck to mitoxantrone therapy at the described doses.

๐Ÿ“œ SIMILAR VOLUMES

Phase II study of mitoxantrone in advanc
Phase II study of mitoxantrone in advanced squamous cell carcinoma of the head and neck
โœ Stephen D. Williams; Robert Birch; Enrique Velez-Garcia; Richard Gams ๐Ÿ“‚ Article ๐Ÿ“… 1985 ๐Ÿ› Springer US ๐ŸŒ English โš– 170 KB

A phase II study of mitoxantrone in squamous cell carcinoma of head and neck origin was conducted. Fiftythree evaluable patients were treated with this agent at a dosage of 5 mg/M2/week. The majority of patients were of high performance status. Twenty-seven patients had received previous chemotherap

A phase II study of piritrexim in patien
A phase II study of piritrexim in patients with advanced squamous head and neck cancer
โœ Wu-Ching Uen; Andrew T. Huang; Robert Mennel; Stephen E. Jones; Monica B. Spauld ๐Ÿ“‚ Article ๐Ÿ“… 1992 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 347 KB ๐Ÿ‘ 3 views

Piritrexim (PTX) is a newly developed lipid-soluble folate antagonist that crosses the cell membrane by a simple, rapid, carrier-independent diffusion process. A Phase II study was conducted to evaluate the activity of PTX in 34 patients with previously chemotherapy-naive squamous cell cancer of the

Phase II trial of mitoxantrone in head a
Phase II trial of mitoxantrone in head and neck cancer
โœ Matti S. Aapro; Davis S. Alberts ๐Ÿ“‚ Article ๐Ÿ“… 1984 ๐Ÿ› Springer US ๐ŸŒ English โš– 136 KB

Mitoxantrone (l,4-dihydroxy-5,8-bis((2-[(2-hydroxyethyl)amino]ethyl)amino)-9, 10 anthracenedione dihydrochloride, NSC 301,739) is a new aminoanthraquinone derivative with clinical activity in the treatment of advanced breast cancer (1, 2), lymphoma (3), and acute leukemia (4). We have carried out a